Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

559 ARTÍCULOS , VIENDO DEL 286 AL 300

Biomembrane-Derived Nanoparticles in Alzheimer's Disease Therapy: A Comprehensive Review of Synthetic Lipid Nanoparticles and Natural Cell-Derived Vesicles

Gao C, Liu Y, Zhang TL, Luo Y, Gao J, Chu JJ, Gong BF, Chen XH, Yin T, Zhang J, Yin Y.

Int J Nanomedicine. 2023 Dec 7;18:7441-7468. doi: 10.2147/IJN.S436774. eCollection 2023.

Cancer drugs with high repositioning potential for Alzheimer's disease

Majeed J, Sabbagh MN, Kang MH, Lawrence JJ, Pruitt K, Bacus S, Reyna E, Brown M, Decourt B.

Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26.

Current Anti-Amyloid-β Therapy for Alzheimer's Disease Treatment: From Clinical Research to Nanomedicine

Zhao Z, Liu Y, Ruan S, Hu Y.

Int J Nanomedicine. 2023 Dec 20;18:7825-7845. doi: 10.2147/IJN.S444115. eCollection 2023.

[Russian experience in using a combination of fixed doses of donepezil and memantine in the treatment of Alzheimer's disease as an observational non-interventional multicenter program]

Kolykhalov IV, Mkhitaryan EA, Fedorova YB, Ponomareva EV, Selezneva ND, Cherdak MA, Dudchenko NG, Seyfedinova AB, Isaev RI, Gavrilova SI, Tkacheva ON.

Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(12):69-75. doi: 10.17116/jnevro202312312169.

Drug Repositioning of Pioglitazone in Management and Improving the Cognitive Function among the Patients With Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis

Basutkar RS, Sudarsan P, Robin SM, Bhaskar V, Viswanathan B, Sivasankaran P.

Neurol India. 2023 Nov-Dec;71(6):1132-1141. doi: 10.4103/0028-3886.391397.

Mechanisms of 3-Hydroxyl 3-Methylglutaryl CoA Reductase in Alzheimer's Disease

Zhou X, Wu X, Wang R, Han L, Li H, Zhao W.

Int J Mol Sci. 2023 Dec 22;25(1):170. doi: 10.3390/ijms25010170.

Systematic review and meta‑analysis of observational studies to check the protective role of non‑steroidal anti‑inflammatory drugs in Alzheimer's disease

Asthana A, Tripathi S, Agarwal R.

Acta Neurobiol Exp (Wars). 2023 Dec 4;83(4):386-394. doi: 10.55782/ane-2023-2467.

[Impact of animal-assisted therapy on well-being in patients with Alzheimer's disease (ELIAUT study)]

Thirion E, Rouissi S, Dauphinot V, Garnier-Crussard A, Coste MH, Krolak-Salmon P.

Geriatr Psychol Neuropsychiatr Vieil. 2023 Dec 1;21(4):506-516. doi: 10.1684/pnv.2023.1134.

Interactions of Polyphenolic Gallotannins with Amyloidogenic Polypeptides Associated with Alzheimer's Disease: From Molecular Insights to Physiological Significance

Khalifa J, Bourgault S, Gaudreault R.

Curr Alzheimer Res. 2023;20(9):603-617. doi: 10.2174/0115672050277001231213073043.

The Potential of a Stratified Approach to Drug Repurposing in Alzheimer's Disease

Anderson C, Bucholc M, McClean PL, Zhang SD.

Biomolecules. 2023 Dec 21;14(1):11. doi: 10.3390/biom14010011.

The effects of deep transcranial magnetic stimulation on Alzheimer's disease: a case report examining cognitive functioning, memory, and QEEG

Shanok NA, Muzac S, Derbin B, Cabeza E, Rodriguez R.

Neurocase. 2023 Jun;29(3):81-86. doi: 10.1080/13554794.2024.2346987. Epub 2024 Apr 27.

Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's Disease

Mazahir F, Yadav AK.

CNS Neurol Disord Drug Targets. 2023;22(4):477-499. doi: 10.2174/1871527321666220420133059.

Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients

Bhattacharya S.

Curr Pharm Biotechnol. 2023;24(9):1108-1121. doi: 10.2174/1385272827666221027103050.

Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial

Quintana-Hernández DJ, Rojas-Hernández J, Santana-Del Pino A, Céspedes Suárez C, Pellejero Silva M, Miró-Barrachina MT, Ibáñez Fernández I, Estupiñán López JA, Borkel LF.

J Alzheimers Dis. 2023;91(1):471-481. doi: 10.3233/JAD-220889.

Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials

Muralidharan KK, Kowalski KG, Tong X, Haeberlein SB, Rajagovindan R, Nestorov I.

J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):45-62. doi: 10.1007/s10928-022-09839-3. Epub 2023 Jan 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias